Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC

Regulatoryrejectedifinatamab deruxtecanNegative

AI Analysis

Summary

Merck and Daiichi Sankyo have withdrawn their accelerated approval request for ifinatamab deruxtecan, an antibody-drug conjugate for lung cancer. Industry analysts view the withdrawal as beneficial for competitors GSK and Roche.

Outcome Details

Accelerated approval request withdrawn

Importance:6/10

Sentiment:

-0.60

ADCaccelerated_approvalwithdrawaloncologylung_cancer

Related Companies

$MRK $DSKYF

Read the original article

Published by BioSpace on September 28, 2026 11:15 AM

Read Original